Cancer BiologybioRxiv
Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects
Alexandria P. Eiken, Audrey L. Smith, Sydney A. Skupa…·Dalia El-Gamal
This paper evaluates SpiD3, a novel spirocyclic dimer, showing potent anti-leukemic effects in CLL cells, including resistance to ibrutinib, by targeting NF-κB signaling and the UPR.